GLP Watchdog

Weight Loss Medications, Drugs & Pills (2026)

Every FDA-approved weight loss medication, drug, and pill in 2026 — GLP-1 receptor agonists for chronic weight management (Wegovy, Zepbound, Foundayo, Saxenda), the type-2-diabetes GLP-1s commonly prescribed off-label (Ozempic, Mounjaro), non-GLP-1 anti-obesity pills (Qsymia, Contrave, Xenical), and the pipeline drugs in late-phase trials. Verified primary-source data, brand by brand.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

About this page

Every drug below is FDA-approved with a published label on DailyMed (NIH) or Drugs@FDA. The mechanism, indication, administration route, and approval-date data are pulled from our primary-source-verified drug database — see each drug's linked guide for verbatim FDA-label quotes, clinical-trial citations, and the editorial verification log. We do not paraphrase indication language and we do not invent comparisons that the published evidence does not support.

Weight loss pills vs weight loss injections

Weight loss medications come in two administration formats: oral pills (taken by mouth) and subcutaneous injections (self-administered, typically once weekly). The choice between them depends on FDA-approved indication, tolerability of needles, dosing convenience, and insurance coverage.

Weight loss pills (oral)

FDA-approved oral weight-loss options as of 2026:

  • Foundayo (orforglipron) — GLP-1 RA, daily tablet, FDA-approved April 2026
  • Rybelsus (oral semaglutide) — GLP-1 RA for type 2 diabetes (off-label for weight loss), daily tablet
  • Qsymia (phentermine + topiramate) — non-GLP-1, daily capsule, FDA-approved 2012
  • Contrave (naltrexone + bupropion) — non-GLP-1, twice-daily tablet, FDA-approved 2014
  • Xenical / alli (orlistat) — non-GLP-1, three times daily, FDA-approved 1999 (Rx) / 2007 (OTC alli)

Weight loss injections (subcutaneous)

FDA-approved injectable weight-loss options:

  • Wegovy (semaglutide 2.4 mg) — once weekly, FDA-approved June 2021
  • Zepbound (tirzepatide) — once weekly, FDA-approved November 2023
  • Saxenda (liraglutide 3 mg) — once daily, FDA-approved December 2014
  • Ozempic (semaglutide for T2D) — once weekly, off-label for weight loss
  • Mounjaro (tirzepatide for T2D) — once weekly, off-label for weight loss

For a deep dive on the GLP-1 receptor agonist drug class specifically — what it is, how it works, every FDA-approved GLP-1, and how brand-name overlaps work — see our GLP-1 complete guide.

GLP-1 receptor agonists indicated for chronic weight management

These are the drugs FDA-approved specifically for weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbid condition.

Wegovy

Semaglutide
Drug class
GLP-1 receptor agonist
Administration
Subcutaneous injection (single-dose pre-filled pen or syringe) or, new in 2026, an oral tablet taken once daily
Manufacturer
Novo Nordisk A/S
FDA indication
Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity; weight reduction in pediatric patients aged 12+; cardiovascular risk reduction in adults with obesity and established cardiovascular disease; noncirrhotic MASH with moderate-to-advanced liver fibrosis in adults (2026). The oral tablet form (2026) covers the cardiovascular risk reduction and adult weight reduction indications only.

FDA status: FDA-approved for chronic weight management in adults with obesity or overweight with comorbidity (June 2021); cardiovascular risk reduction in adults with established CVD (March 2024); weight reduction in pediatric patients aged 12+ (Dec 2024); noncirrhotic MASH with moderate-to-advanced liver fibrosis in adults (2026); and — new in 2026 — an oral tablet form for cardiovascular risk reduction or weight reduction in adults, alongside the original injection

Full Wegovy guide →

Zepbound

Tirzepatide
Drug class
GIP and GLP-1 receptor agonist (dual incretin)
Administration
Subcutaneous injection (single-dose pre-filled pen and vial)
Manufacturer
Eli Lilly and Company
FDA indication
Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity; obstructive sleep apnea in adults with obesity

FDA status: FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity (November 2023)

Full Zepbound guide →

Foundayo

Orforglipron
Drug class
GLP-1 receptor agonist (oral non-peptide small molecule)
Administration
Oral, once daily
Manufacturer
Eli Lilly and Company
FDA indication
Chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity

FDA status: FDA-approved for chronic weight management in adults with obesity, or overweight with weight-related medical problems, alongside a reduced-calorie diet and increased physical activity (April 1, 2026). Not approved for pediatric use. Cannot be used with other GLP-1 receptor agonists.

Full Foundayo guide →

GLP-1s indicated for type 2 diabetes — commonly used off-label for weight loss

These drugs are FDA-approved for glycemic control in type 2 diabetes, not for weight loss alone. They are commonly prescribed off-label for weight loss when weight-management-indicated drugs are unavailable or not covered. Off-label prescribing is legal and common, but often not covered by insurance for this use.

Ozempic

Semaglutide
Drug class
GLP-1 receptor agonist
Administration
Subcutaneous injection (multi-dose pre-filled pen)
Manufacturer
Novo Nordisk A/S
FDA indication
Glycemic control in type 2 diabetes mellitus; cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease

FDA status: FDA-approved for glycemic control in type 2 diabetes (December 2017); FDA-approved to reduce cardiovascular risk in adults with T2DM and established CVD (2020). Weight loss is off-label use.

Full Ozempic guide →

Mounjaro

Tirzepatide
Drug class
GIP and GLP-1 receptor agonist (dual incretin)
Administration
Subcutaneous injection (single-dose pre-filled pen)
Manufacturer
Eli Lilly and Company
FDA indication
Glycemic control in adults with type 2 diabetes mellitus

FDA status: FDA-approved for type 2 diabetes (May 2022). Off-label use for weight loss is common; the weight management indication is covered by Zepbound (FDA-approved November 2023).

Full Mounjaro guide →

Pipeline: drugs in late-stage clinical trials

These investigational drugs have published phase 2 or phase 3 trial data but are not yet FDA-approved. For trial-by-trial NCT IDs, primary completion dates, and verified topline results, see our comprehensive GLP-1 Pipeline Tracker (2026). Quick summary below:

  • Retatrutide — Eli Lilly. Triple agonist (GLP-1 / GIP / glucagon). The strongest weight-loss readout in any GLP-1 trial to date. See our retatrutide evidence article.
  • CagriSema — Novo Nordisk. Cagrilintide (amylin analog) + semaglutide combination. See the CagriSema REDEFINE results.
  • MariTide (maridebart cafraglutide) — Amgen. GLP-1 / GIP receptor modulator with monthly dosing. See the GLP-1 pipeline article.
  • Survodutide — Boehringer Ingelheim & Zealand Pharma. GLP-1 / glucagon dual agonist. Coverage in the same pipeline article.
  • Ecnoglutide — Sciwind. Long-acting GLP-1 RA in late-stage trials. Coverage in the pipeline article.

Other FDA-approved anti-obesity medications

The FDA has approved additional non-GLP-1 medications for chronic weight management — including Saxenda (liraglutide), Qsymia (phentermine + topiramate), Contrave (naltrexone + bupropion), Xenical / alli (orlistat), Plenity (cellulose hydrogel device), and Imcivree (setmelanotide for rare genetic obesity). We link to canonical FDA sources below while our verification queue advances.

Authoritative FDA-published landscape: NIDDK — Prescription Medications to Treat Overweight & Obesity. Drugs@FDA database for current label of any specific drug. We'll add dedicated guides for each of the older AOMs as our verification queue advances.

Patent cliff & generic timeline

Two FDA-approved generic GLP-1 receptor agonists already exist in the US: Hikma generic liraglutide referencing Victoza (December 2024) and Teva generic liraglutide 3 mg referencing Saxenda (August 2025). Wegovy, Ozempic, Rybelsus, Mounjaro, Zepbound, and Foundayo remain patent-protected; semaglutide composition-of-matter is widely modeled to expire in the early 2030s, and tirzepatide / orforglipron run later. Trulicity is on the BLA biosimilar pathway, not the generic pathway.

GLP-1 generics 2026: when will each drug go generic? Patent cliff tracker

Common questions about weight loss medications

Where to go next

Weight loss injections guide →
Every FDA-approved injectable option (Wegovy, Zepbound, Saxenda) plus off-label T2D injectables, the pipeline, cost, and the cross-trial caveats SURMOUNT-1 vs STEP-1 vs SCALE require.
State-by-state Medicaid coverage →
Per-state Medicaid GLP-1 coverage deep-dives anchored in primary-source PDLs and provider notices. Start with the Texas anchor article — links to California, New York, and Florida deep-dives are inside.
Best semaglutide providers →
Compounded and brand-name semaglutide telehealth providers, ranked by price + transparency.
Best tirzepatide providers →
Compounded and brand-name tirzepatide telehealth providers, ranked by price + transparency.
Live GLP-1 pricing index →
Brand list prices vs compounded cash-pay vs savings-card paths across every channel we track.
Insurance coverage by insurer →
Cigna, Aetna, UnitedHealthcare, Humana, Anthem BCBS, Kaiser, Medicare, Medicaid — verified PA criteria and copay data.
Research library →
Evidence-based articles on side effects, drug interactions, long-term outcomes, peri-operative guidance, and bariatric vs GLP-1 decision support — all primary-source verified.